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Therapeutics, Targets, and Chemical Biology
Novel Therapeutic Strategy to Prevent Chemotherapy-
Induced Persistent Sensory Neuropathy By TRPA1 Blockade
Gabriela Trevisan1,2, Serena Materazzi2, Camilla Fusi2, Alessandra Altomare4, Giancarlo Aldini4,
Maura Lodovici3, Riccardo Patacchini5, Pierangelo Geppetti2, and Romina Nassini2
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and painful adverse reaction of cancer
treatment in patients that is little understood or treated. Cytotoxic drugs that cause CIPN exert their
effects by increasing oxidative stress, which activates the ion channel TRPA1 expressed by nociceptors. In
this study, we evaluated whether TRPA1 acted as a critical mediator of CIPN by bortezomib or oxaliplatin
in a mouse model system. Bortezomib evoked a prolonged mechanical, cold, and selective chemical
hypersensitivity (the latter against the TRPA1 agonist allyl isothiocyanate). This CIPN hypersensitivity
phenotype that was stably established by bortezomib could be transiently reverted by systemic or local
treatment with the TRPA1 antagonist HC-030031. A similar effect was produced by the oxidative stress
scavenger a-lipoic acid. Notably, the CIPN phenotype was abolished completely in mice that were
genetically deficient in TRPA1, highlighting its essential role. Administration of bortezomib or oxaliplatin,
which also elicits TRPA1-dependent hypersensitivity, produced a rapid, transient increase in plasma of
carboxy-methyl-lysine, a by-product of oxidative stress. Short-term systemic treatment with either HC-
030031 or a-lipoic acid could completely prevent hypersensitivity if administered before the cytotoxic
drug. Our findings highlight a key role for early activation/sensitization of TRPA1 by oxidative stress by-
products in producing CIPN. Furthermore, they suggest prevention strategies for CIPN in patients
through the use of early, short-term treatments with TRPA1 antagonists. Cancer Res; 73(10); 3120–31.
2013 AACR.
Introduction
Several anticancer medicines evoke sensory adverse events,
collectively referred to as chemotherapy-induced peripheral
neuropathy (CIPN), which are represented by sensory symp-
toms (from paresthesias, allodynia, and hyperalgesia to severe
pain). In addition to impairing patient quality of life, CIPNmay
lead to dose-limitation or even discontinuation of anticancer
treatment (1). No effective therapy is currently available to
treat or prevent CIPN, most likely because the underlying
mechanisms are poorly understood. A host of hypotheses has
been proposed to explain CIPN, including mitochondrial dys-
function, increased content of oxidative substances, and
altered function of different ion channels (2–7). Nonetheless,
no unified mechanism that may reconcile results of clinical
investigation and findings obtained in experimental animals
has been advanced so far.
Chemotherapeutic drugs, which produce CIPN, are known
to increase oxidative stress and reactive oxygen, nitrogen, or
carbonyl species (ROS, RNS, and RCS, respectively) and treat-
ment with antioxidant substances has been shown to reduce
sensory hypersensitivity in experimental animals and to exhib-
it some degree of protection in patients with CIPN (3, 7–10).
The transient potential receptor ankyrin 1 (TRPA1) is a non-
selective cation channel, coexpressed with TRP vanilloid 1
(TRPV1) in a subset of C-fiber nociceptors, where it functions
as a multimodal sensor to noxious stimuli (11, 12). TRPA1
shows a unique sensitivity for an unprecedented number of
endogenous reactive molecules produced at sites of tissue
injury or inflammation, which include ROS, RNS, and RCS
(13–16).
Bortezomib is a proteasome inhibitor used in different types
of cancer (17). CIPN has emerged as a major complication of
bortezomib therapy, which usually appears in the first courses
of therapy with a number of sensory and painful symptoms,
including reduced threshold to mechanical and cold stimuli
(18, 19). No satisfactory explanation or effective treatment
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exists for bortezomib-evoked CIPN (20, 21). As described for
other chemotherapeutics, bortezomib has been reported to
increase oxidative stress (22, 23).
In the present study, first, we investigated the role of
oxidative stress and TRPA1 in a mouse model of CIPN evoked
by bortezomib. Biochemical, pharmacologic, and genetic find-
ings show that TRPA1 is necessary and sufficient to develop
andmaintain bortezomib-evokedmechanical, cold, and chem-
ical hypersensitivity in mice. Second, we showed that early and
short-term pharmacologic TRPA1 blockade totally prevented
the sensory neuropathy evoked by bortezomib and oxaliplatin
(previously shown to produce a TRPA1-dependent hypersen-
sitivity inmice; refs. 5, 6, 24), thus opening new perspectives for
CIPN prevention and treatment.
Materials and Methods
Animals
Animal experiments were carried out according to Italian
legislation (DL 116/92) and European Communities Council
Directive (86/609/EEC). Studies were conducted under the
permit (number 143/2008-B and 204/2012-B, University of Flor-
ence, Florence, Italy) approved by the Italian National Commit-
tee for Animal Research. C57BL/6 mice (male, 25–30 g; Harlan
Laboratories), wild-type (Trpa1þ/þ), or TRPA1-deficient mice
(Trpa1/; 25–30 g; Jackson Laboratories) were used. Animals
were housed in a temperature- and humidity-controlled vivar-
ium (12-hour dark/light cycle, free access to food and water).
Behavioral experiments were done in a quiet, temperature-
controlled room (20–22C) between 9 a.m. and 5 p.m., and were
conducted by an operator blinded to the genotype and the
status of drug treatment. Animals were sacrificed with a high
dose of intraperitoneal (i.p.) sodium pentobarbital (200 mg/kg).
Reagents
If not otherwise indicated, all reagents were from Sigma-
Aldrich. HC-030031 [2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahy-
dro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide; Supple-
mentary Fig. S1A] was synthesized as previously described
(15). HC-067047 (2-Methyl-1-[3-(4-morpholinyl)propyl]-5-phe-
nyl-N-[3-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide;
Supplementary Fig. S1B) was obtained from Tocris Bioscience,
and bortezomib was purchased from LC Laboratories.
Chemotherapy-induced painful neuropathy models
Previous studies have described rat and mouse models of
peripheral neuropathy induced by repeated and prolonged
administration of bortezomib (25–28). On the basis of these
findings, in the first series of experiments, we exploredwhether
a single administration of bortezomib produced mechanical
and cold hypersensitivity in mice, as observed for different
chemotherapeutic agents including oxaliplatin, paclitaxel, and
vincristine (4, 6, 29). After habituation and baseline measure-
ments of pain sensitivity, animals were randomized into
treatment groups. C57BL/6, Trpa1þ/þ, or Trpa1/mice were
treatedwith a single intraperitoneal administration of different
doses of bortezomib (0.2, 0.5, and 1mg/kg), or vehicle (dimethyl
sulfoxide, DMSO 1%; ref. 27). Bortezomib, formulated at a
concentration of 1 mg/mL, was first dissolved in a vehicle
containing DMSO, and the volume was adjusted to 10 mL/kg
to a final concentration of 1% DMSO, then diluted in isotonic
saline (NaCl 0.9%) to obtain lower doses. A different group of
C57BL/6 mice was treated with a single administration of
oxaliplatin (3 mg/kg, i.p.) or its vehicle (isotonic saline, NaCl
0.9%; ref. 6). No weight loss was observed in mice after
bortezomib or oxaliplatin treatment throughout the dura-
tion of the experiments. Effects induced by bortezomib and
oxaliplatin were tested for 14 and 30 days (starting 6 hours
after drug administration), respectively. Baseline values
for nociceptive tests were observed before chemotherapy
treatment.
Nociceptive tests
Von frey hair test. Mechanical threshold wasmeasured in
C57/BL6, Trpa1þ/þ, or Trpa1/ mice after a single adminis-
tration of bortezomib or oxaliplatin by using the up-and-down
paradigm (30). Mechanical nociceptive threshold was deter-
mined before (basal level threshold) and after different treat-
ments. The 50% mechanical paw withdrawal threshold (in g)
response was then calculated from these scores, as previously
described (30, 31).
Hot plate test. Thepaw thermal hyperalgesiawas assessed
in C57/BL6, Trpa1þ/þ, or Trpa1/ by placing animals on a hot
plate (UgoBasile) with the temperature adjusted to 50 0.1C
(32). The latency to thefirst hind paw licking orwithdrawalwas
taken as an index of nociceptive threshold. The cut-off time
was set at 30 seconds, to avoid damage to the paw. The paw-
withdrawal latency to the first response was reported as mean
of 2 different trials.
Cold stimulation. Cold allodynia was assessed in C57/
BL6,Trpa1þ/þ, orTrpa1/ bymeasuring the acute nocifensive
response to the acetone-evoked evaporative cooling as previ-
ously described (29). Briefly, a droplet (50 mL) of acetone,
formed on the flat-tip needle of a syringe, was gently touched
to the plantar surface of the mouse hind paw, and the time
spent in elevation and licking of the plantar region over a 60-
second period wasmeasured. Acetone was applied 3 times at a
10- to 15-minute intervals, and the average of elevation/licking
time was calculated.
Chemical hyperalgesia. Nociceptive behavior was
assessed by measuring spontaneous nociceptive response
induced by intraplantar (i.pl.) injection (20 mL) of sub-thresh-
old doses of allyl isothiocyanate (AITC; 1 nmol/paw), capsaicin
(0.01 nmol/paw), hypotonic saline (NaCl, 0.45%), or prosta-
glandin E2 (PGE2, 0.3 nmol/paw) at day 7 after the adminis-
tration of bortezomib or its vehicle. Immediately after the
injection, mice were placed inside a Plexiglas chamber and the
total time spent licking and lifting the injected hind paw was
recorded for 5minutes (AITC, capsaicin, and hypotonic saline),
or 20 minutes (PGE2). Previous experiments conducted in our
laboratory and previous findings (33, 34) suggested subthresh-
old doses that do not cause nociception in na€ve mice.
Rotarod test
Locomotor function, coordination, and sedation of animals
were tested by using a rotarod apparatus (UgoBasile). The test
was done as previously described (35). Briefly, 24 hours before
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the experiments, the animals were trained on the rotarod
apparatus, programmed at 8 rpm, until they remained without
falling for 60 seconds. The day of the experiment, the latency
(seconds) to the first fall and the number of falls were recorded.
Cut-off time was 240 seconds.
Treatment protocols
In a first set of experiments, intragastric (i.g.) HC-030031
(300mg/kg) or its vehicle (0.5% carboxymethyl cellulose, CMC),
HC-067047 (10 mg/kg, i.p.) or its vehicle (2.5% DMSO), or
a-lipoic acid (100 mg/kg, i.g.) or its vehicle (0.5% CMC), were
administered at day 7 after the administration of bortezomib
(1 mg/kg, i.p.) or its vehicle. In a second set of experiments,
i.pl. HC-030031 (100 mg/paw, 20 mL; ref. 36), a-lipoic acid
(10 mg/paw, 20 mL; ref. 3), or vehicle (20 mL/paw, 1% DMSO
in isotonic saline, NaCl 0.9%) were injected at day 3 or day 7
after the administration of oxaliplatin or bortezomib (see
earlier section for dosing), respectively. In a third set of
experiments, HC-030031 (300 mg/kg, i.g.), a-lipoic acid (100
mg/kg, i.g.), or their respective vehicles, were administered 15
minutes before the administration of bortezomib, oxaliplatin,
or their vehicles and treatment was repeated 3 times at
approximately 90-minute intervals each after the administra-
tion of bortezomib or oxaliplatin. In a fourth and final set of
experiments, a group ofmicewas treatedwithHC-030031 or its
vehicle 15minutes before and shortly (3 times at approximately
90-minute intervals each) after a first bortezomib (1 mg/kg,
i.p.) or vehicle administration. At day 6, each group of mice
received a second treatment identical to that administered at
day 1, except formice treated at day 1with bothHC-030031 and
bortezomib, which were subdivided into 2 additional groups.
One group was treated a second time with either HC-030031
(300 mg/kg, i.g.) and the second with its vehicle 15 minutes
before and shortly after (3 times at approximately 90-minute
intervals each) bortezomib administration (Fig. 6A).
Isolation of primary sensory neurons and calcium
imaging experiments
Primary dorsal root ganglia (DRG) from C57/BL6 adult mice
were cultured as previously described (29). Briefly, lumbosacral
(L5–S2) ganglia were bilaterally excised under a dissection
microscope. Ganglia were digested using 1 mg/mL of collage-
nase type 1A and 1 mg/mL of papain in Hank's Balanced Salt
Solution (25 minutes, 37C). Neurons were pelleted and resus-
pended in Ham's-F12 containing 10% FBS, 100 U/mL of pen-
icillin, 0.1 mg/mL of streptomycin, and 2 mmol/L glutamine,
dissociated by gentle trituration, and plated on glass coverslips
coated with poly-L-lysine (8.3 mmol/L) and laminin (5 mmol/L).
Neurons were cultured for 3 to 4 days.
Cells were incubated with 5 mmol/L Fura-2AM ester for 30
minutes at 37C. Intracellular calcium concentration ([Ca2þ]i)
was measured on a Nikon Eclipse TE2000U microscope. Fluo-
rescence was measured during excitation at 340 and 380 nm,
and after correction for the individual background fluores-
cence signals, the ratio of the fluorescence at both excitation
wavelengths (Ratio340/380) was monitored. Experiments were
conducted using a buffer solution containing (in mmol/L): 150
NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, 10 HEPES and
titrated to pH 7.4 with 1N NaOH. Cells were challenged with
bortezomib (10, 50, and 100 mmol/L) or their respective vehi-
cles (0.01, 0.5, and 1%DMSO), AITC (30 mmol/L), and capsaicin
(0.1 mmol/L) to identify nociceptive neurons. In another series
of experiments, DRG neurons were incubated with bortezomib
(10 or 100 mmol/L) or its vehicle (0.01 and 0.1% DMSO) for 2
hours and then challenged with AITC (10 or 30 mmol/L).
Results are expressed as the increase of Ratio340/380 over the
baseline normalized to the maximum effect induced by iono-
mycin (5 mmol/L) added at the end of the experiment.
Protein extraction and Western immunoblotassay
Spinal cord, DRGs, and hind paw skin were obtained from
mice treated with bortezomib or its vehicle at day 7 post
treatment. Tissue samples were homogenized in lysis buffer
containing (in mmol/L): 50 Tris, 150 NaCl, 2 EGTA, 100 NaF, 1
Na3VO4, 1% Nonidet P40, pH 7.5, and complete protease
inhibitor cocktail (Roche). Lysates were centrifuged at
14,000g at 4C for 45 minutes. Protein concentration in super-
natants was determined using DC protein assay (Bio-Rad).
Samples with equal amounts of proteins (30 mg) were then
separated by 10% SDS-PAGE electrophoresis, and the resolved
proteins were transferred to a polyvinylidenedifluoride mem-
brane (Merck Millipore Billerica). Membranes were incubated
with 5% dry milk in Tris buffer containing 0.1% Tween 20
(TBST; 20mmol/L Tris, pH 7.5, 150mmol/L NaCl) for 1 hour at
room temperature, and incubated with rat polyclonal primary
antibody for TRPA1 detection (1:200; Novus Biologicals), or
mouse monoclonal primary antibody for b-actin (1:6,000;
Thermo Scientific), at 4C overnight. Membranes were then
probed with goat anti-mouse or donkey anti-rabbit IgG con-
jugated with horseradish peroxidase (Bethyl Laboratories Inc.)
for 50 minutes at room temperature. Finally, membranes were
washed 3 times with TBST, and bound antibodies were
detected using chemiluminescence reagents (ECL; Pierce,
Thermo Scientific). The density of specific bands was mea-
sured using an image-processing program (ImageJ 1.32J,
Wayne Rasband) and normalized against a loading control
(b-actin).
Carboxy-methyl-lysine adducts measurement in plasma
Briefly, blood samples from C57/BL6 mice, taken 1, 3, 6, and
24 hours after the administration of bortezomib (1mg/kg, i.p.),
oxaliplatin (3 mg/kg, i.p.), or their vehicles (1% DMSO and
isotonic saline, NaCl 0.9%, respectively), were centrifuged at
3,500g for 10 minutes, and plasma was used for the carboxy-
methyl-lysine (CML) protein adduct ELISA assay. CML protein
adducts content in plasma was measured using as ELISA kit
(OxiSelect ELISA Kit, Cell Biolabs Inc. Valter Occhiena S.R.L.)
according to the manufacturer's instructions.
Statistical analysis
Data are presented as mean  SEM. Statistical analysis was
carried out by the unpaired 2-tailed Student t test for compar-
isons between 2 groups, the ANOVA, followed by the post hoc
Bonferroni test for comparisons ofmultiple groups. P value less
than 0.05 was considered statistically significant (GraphPadPr-
ism version 5.00). To meet ANOVA assumptions, mechanical
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allodynia data were subjected to log transformation before
statistical analysis.
Results
Bortezomib administration produces persistent
mechanical cold and chemical hypersensitivitymediated
by TRPA1
Administration of a single dose (0.2, 0.5, and 1 mg/kg, i.p.) of
bortezomib induced a dose-dependent mechanical and cold
hypersensitivity in C57BL/6 mice (Fig. 1A and B). Reduced
mechanical thresholdwas observed after bortezomib (1mg/kg,
i.p.) injection as early as 6 hours and lasted until 11 days after
treatment (Fig. 1A). Similar results were obtained for cold
allodynia, which was evident at day 1 and persisted until day 11
after bortezomib injection (Fig. 1B). Bortezomib administra-
tion (1 mg/kg, i.p.) did not affect the heat threshold of mice at
any time point, from 6 hours to 14 days after treatment.
Nociception time to heat stimulus was 19.7 0.8 seconds and
17.2  1.0 seconds at baseline and 7 days after bortezomib
treatment, respectively (n¼ 8–10mice, P > 0.05, Student t test).
Next, we investigated whether TRPA1 activation is involved
in mechanical and cold hypersensitivity induced by bortezo-
mib. Systemic treatment with the TRPA1 selective antagonist
HC-030031 (300 mg/kg, i.g.; ref. 37) at day 7 after bortezomib
treatment completely, but transiently, reverted both mechan-
ical hyperalgesia and cold allodynia. Significant inhibition was
observed from 30 to 120 minutes after HC-030031 treatment,
with maximum reduction (98 12% and 90 6% for mechan-
ical hyperalgesia and cold allodynia, respectively) 60 minutes
post dosing (Fig. 1C and D). Systemic treatment with HC-
030031 (300 mg/kg, i.g.) at day 7 after treatment with borte-
zomib (0.2 or 0.5 mg/kg, i.p.) completely but transiently
reverted both mechanical hyperalgesia and cold allodynia
(data not shown).
Given that we, as well as others (29, 38), have found that
mechanical and cold hypersensitivity evoked by paclitaxel was
mediated by both TRPA1- andTRPV4-dependentmechanisms,
we tested whether the TRPV4 channel contributes to borte-
zomib-induced sensory hypersensitivity by using a selective
TRPV4 antagonist, HC-067047 (10 mg/kg, i.p.; ref. 39). HC-
067047, at a dose able to reduce mechanical hyperalgesia
evoked by paclitaxel (29), failed to affect bortezomib-evoked
hypersensitivities (data not shown). Therefore, present phar-
macologic evidence indicates an exclusive role for TRPA1 in
bortezomib-induced mechanical allodynia and cold hypersen-
sitivity in mice, whereas it rules out a contribution by TRPV4.
Figure 1. Bortezomib induces mechanical allodynia and cold hypersensitivity via TRPA1 activation in mice. A single dose of bortezomib (BTZ; 0.2, 0.5,
and 1 mg/kg i.p.) induces in C57BL/6 mice a dose- and time-dependent mechanical (A) and cold (B) allodynia, which starts at 6 hours or day 1,
respectively, and persists until day 11 after BTZ (1 mg/kg) administration. At day 7 after BTZ administration, the selective TRPA1 receptor antagonist,
HC-030031 (HC; 300 mg/kg i.g.), completely reverses the mechanical (C) and cold (D) allodynia with a maximum effect, 60 minutes after dosing. BTZ
treatment produces in Trpa1þ/þmice mechanical (E) and cold (F) allodynia similar to those observed in C57BL/6. These effects are completely absent in
Trpa1/mice (E and F). Veh, vehicle of BTZ or HC. Values are mean  SEM of 8 to 10 mice. #, P < 0.05 versus VehBTZ, Student t test in A
and B; , P < 0.05 versus VehBTZ-VehHC in C and D and VehBTZ-Trpa1þ/þ in E and F; x, P < 0.05 versus BTZ-VehHC in C and D and BTZ-Trpa1/in E and F;
one-way ANOVA and Bonferroni test. BL, baseline withdrawal threshold.
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More importantly, we found that bortezomib treatment
(1 mg/kg, i.p.) produced mechanical hyperalgesia and cold
allodynia in Trpa1þ/þ mice with an identical time course to
that observed in C57BL/6 mice, an effect that was completely
absent in Trpa1/ mice (Fig. 1E and F).
In addition, we wondered whether bortezomib could
cause selective chemical hypersensitivity to TRPA1 agonists.
The study of the effects produced by sub-threshold doses of
AITC (TRPA1 agonist), capsaicin (TRPV1 agonist), PGE2
(EP1-4 receptor agonist), or hypotonic saline (which can
stimulate TRPV4) showed that bortezomib treatment selec-
tively increased the nociceptive behavior evoked by AITC
(Fig. 2A). In fact, responses to capsaicin, PGE2, and hypo-
tonic saline were similar in both vehicle- and bortezomib-
treated animals (Fig. 2B–D). As expected, in TRPA1-deficient
mice treated with bortezomib or its vehicle, AITC failed to
evoke any nociceptive response (data not shown).
Bortezomib does not affect TRPA1 receptor expression
and does not directly activate TRPA1
TRPA1 expression has been found to vary in different painful
conditions, including models of CIPN (9, 40). Therefore, we
Figure 2. Bortezomib enhances allyl isothiocyanate-evoked nocifensive behavior but does not increase TRPA1 expression or directly activate TRPA1.
Nociceptive behavior produced by a sub-threshold dose of intraplantar (i.pl.; 20 mL) injection of allyl isothiocyanate (AITC; 1 nmol/paw; A) in mice is increased
7 days after BTZ (1 mg/kg i.p.). Responses to subthreshold doses of capsaicin (CPS; 0.01 nmol/paw; B), hypotonic saline (NaCl, 0.45%; C), and
PGE2 (0.3 nmol/paw; D) are not affected by BTZ. Values are mean  SEM of 8 to 10 mice. , P < 0.05 versus VehBTZ-AITC in A; Student t test. E, TRPA1
protein content analyzed by Western blotting is not different in tissue homogenates of spinal cord, DRGs, and hind paw skin obtained from mice on
day 7 after treatment with BTZ or its vehicle (Veh). Values are mean SEM of 3 samples, Student t test. Equally loaded protein was checked by expression of
b-actin. A representativeblot is shown.BTZ (10, 50, or 100mmol/L) fails to evoke any visible intracellular calcium (Ca2þ)I response inCPS (0.1mmol/L)-sensitive
DRG neurons, which otherwise responded to AITC (F, G). Trace represents an average of 10 neurons. H, in vitro preexposure to BTZ (100 mmol/L for
2 hours) does not affect themagnitudeof the response, and thenumber of neurons responding toAITC (10 and30mmol/L). Veh is the vehicle of BTZ. Values are
meanSEMof n > 30 neurons. Numbers indicate AITC-responding cells/CPS-responding cells. ,P < 0.05 versus Veh; one-way ANOVA andBonferroni test.
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evaluated, by Western blotting, the expression of TRPA1
receptor in different tissues. At day 7 after administration,
when hypersensitivity was at its maximum, TRPA1 immuno-
reactivity in the spinal cord, DRG, and hind paw skin of mice
treated with bortezomib or its vehicle, were similar (Fig. 2E).
To test the hypothesis that bortezomib directly activates the
TRPA1 receptor, we studied the ability of bortezomib to evoke
calcium responses in cultured mouse DRG neurons. Bortezo-
mib (10, 50, or 100 mmol/L) failed to evoke any calcium
response in capsaicin-sensitive DRG neurons (Fig. 2F and
G), which otherwise responded to the TRPA1 agonist AITC
(30 mmol/L). In vitro pre-exposure to bortezomib (100 mmol/L
for 2 hours) did not affect the magnitude or the number of
neurons responding to AITC (10 and 30 mmol/L; Fig. 2H).
a-Lipoic acid transiently reverts bortezomib-evoked
hypersensitivity
As reported for other anticancer drugs, such as oxalipla-
tin, paclitaxel, and others, there is evidence that bortezomib
also produces oxidative stress (20, 21, 25, 41, 42). Therefore,
we hypothesized that reactive molecules generated by the
oxidative stress burst produced by bortezomib administra-
tion could be the underlying mechanism by which the
anticancer drug induces TRPA1-dependent mechanical and
cold hypersensitivity.
We observed that administration ofa-lipoic acid (100mg/kg,
i.g.) completely abated mechanical hyperalgesia and cold
allodynia evoked at day 7 after bortezomib treatment.
Significant effect of a-lipoic acid was observed from 30 to
120 minutes after treatment, with maximum inhibition (73 
9% and 77 6% formechanical hyperalgesia and cold allodynia,
respectively) 60 minutes post dosing (Fig. 3A and B).
Local treatment with HC-030031 or a-lipoic acid
transiently reverts bortezomib- or oxaliplatin-induced
hypersensitivity
It has been reported that i.pl. injection of a-lipoic acid
reduces oxaliplatin-elicited nociception (3). In the present
study, we observed that i.pl. injection of HC-030031 (100 mg/
paw) or a-lipoic acid (10 mg/paw) completely reduced borte-
zomib-induced mechanical and cold allodynia (Fig. 3C and D).
In addition, we found that mechanical and cold allodynia
elicited by oxaliplatin were markedly decreased by i.pl. injec-
tion of HC-030031 and a-lipoic acid (Fig. 3E and F). Contra-
lateral paw thresholds to mechanical or cold stimuli were not
affected by the i.pl. injection of HC-030031 ora-lipoic acid (Fig.
3C–F). Administration of HC-030031 or a-lipoic acid (i.pl.) did
not produce any appreciable effect in animals treated with the
vehicle of bortezomib or oxaliplatin (data not shown).
Bortezomib and oxaliplatin increase plasma level of
carboxy-methyl-lysine
Systemic oxidative stress was evaluated by measuring the
serum content of Ne-carboxy-methyl-lysine (CML) protein
adducts. CML is the reaction product between lysine and
glyoxal, an a-ketoaldehyde intermediate formed by ascorbate
autoxidation, lipid peroxidation, and oxidative degradation of
glucose and degradation of glycated proteins. Due to the fact
that CML is formed from either carbohydrates or lipids oxi-
dation, it has been termed as an either advanced glycation or
lipoxidation endproducts (EAGLE) modification. CML may be
considered as a general marker of oxidative stress and, so far, it
is widely used to measure oxidative stress in different path-
ophysiologic conditions (43). Bortezomib administration pro-
duced a transient increase in plasma CML levels. One hour
after bortezomib injection, CML increased by 64% over base-
line value, and returned to basal values at 3 hours after
treatment (Fig. 4A). Similar to bortezomib, oxaliplatin admin-
istration produced a transient increase in plasma CML levels,
which was observed at 1 hour (55% over the baseline) and 3
hours (63% over the baseline), and returned to basal levels 6
hours after treatment (Fig. 5A).
Early and short-term treatment with HC-030031 or
a-lipoic acid completely prevents bortezomib- and
oxaliplatin-evoked hypersensitivity
We investigated whether treatment with a TRPA1 antago-
nist or a ROS scavenger given shortly before and after anti-
cancer drug administration could prevent the development of
persistent mechanical, cold, and chemical hypersensitivity. To
test this hypothesis HC-030031 (300mg/kg, i.g.) ora-lipoic acid
(100mg/kg, i.g.), were given respectively, 15minutes before and
3 times every 90 minutes after bortezomib or oxaliplatin
administration. HC-030031 totally prevented the development
of chemical hypersensitivity and mechanical and cold allody-
nia evoked by bortezomib (Fig. 4B, D, and E) and oxaliplatin
(Fig. 5B, D, and E). Similarly, a-lipoic acid prevented chemical
hypersensitivity and mechanical and cold allodynia evoked by
bortezomib (Fig. 4C, F, and G) and oxaliplatin (Fig. 5C, F, and
G). Repeated i.g. administration of TRPA1 antagonist (HC-
030031, 300 mg/kg, i.g.) did not affect forced locomotion of
animals, as observed by the rotarod test. HC-030031- and
vehicle-treated animals did not show any fall during the test
(data not shown).
Mice, protected by early and short-term treatment with
HC-030031, were rechallenged 6 days after a first treatment
with bortezomib with a second bortezomib administration
(1 mg/kg, i.p.). In these mice, a second early and short-term
treatment with HC-030031 again totally prevented the devel-
opment of mechanical and cold hypersensitivity (Fig. 6B and
C). In contrast, mice treated with HC-030031 vehicle did not
show protection against the hypersensitivity evoked by the
second administration of bortezomib. Mice treated with bor-
tezomib and HC-030031 vehicle developed mechanical and
cold hypersensitivity, a response that further increased at the
second treatment with bortezomib and HC-030031 vehicle
(Fig. 6B and C).
Discussion
In the present study in mice, we found that 1 single admin-
istration of bortezomib produced an early and prolonged
mechanical and cold hypersensitivity that started 6 hours after
and lasted for 11 days after bortezomib administration. With a
slight difference in duration, the effect of bortezomib was
practically identical to that previously reported for oxaliplatin
(6). A number of preclinical studies and clinical investigations
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have shown that bortezomib, like oxaliplatin and paclitaxel,
increases ROS and their by-products in plasma, cells, and
tissues of treated animals or patients, and that ROS scavengers
show some degree of protection against CIPN or its rodent
counterpart (3, 7–10, 44). Two observations suggest that
oxidative stress mediates bortezomib-evoked sensory neurop-
athy. First, the ROS scavenger, a-lipoic acid, completely
reversed the established (at day 7 after drug administration)
mechanical and cold hypersensitivity evoked by bortezomib.
Second, bortezomib and oxaliplatin produced an early and
transient (1–3 hours after drug administration) increase in the
plasma levels of 1 major by-product of oxidative stress, CML.
The finding that oxaliplatin administration also increased
plasma oxidative stress by-products is consistent with the
previously reported role of oxidative stress in oxaliplatin-
evoked sensory neuropathy (6).
TRPA1 has been identified as a sensor of oxidative stress, in
as much as it is activated by an unprecedented series of ROS,
RNS, or RCS (16, 45, 46). Thus, we hypothesized that oxidative
stress by-products, generated by bortezomib, may target the
TRPA1 channel in sensory nerve terminals. Indeed, both
pharmacologic and genetic findings indicate that TRPA1 plays
a key role in bortezomib-evoked mechanical and chemical
hyperalgesia and cold allodynia, as these phenomena were
completely reverted when they were at their maximum, for
example, at day 7 after treatment, by a TRPA1 antagonist and
were completely absent in TRPA1-deleted mice. The key
contribution of TRPA1 in mechanical, chemical, and cold
Figure 3. Systemic or local
administration of a-lipoic acid
(a-LA) and local administration of
HC-030031 (HC) transiently
reverse BTZ-evoked mechanical
and cold hypersensitivity in mice.
At day 7 after BTZ (1 mg/kg i.p.),
a-LA (100 mg/kg i.g.) completely
reverses the mechanical (A) and
cold (B) allodynia with a maximum
effect at 60 minutes post dosing.
Veh, vehicle of BTZ or a-LA acid.
C and E, HC (100 mg/paw, i.pl.
20 mL) or a-LA (10 mg/paw) reduce
the mechanical allodynia induced
by BTZ or oxaliplatin (OXA;
3 mg/kg, i.p.) in the paw ipsilateral
(ipsi) to the injection. D and F, in the
contralateral (contra) side, the paw
threshold to mechanical stimuli is
not affected by local HC or a-LA.
Local HC or a-LA acid treatment
produces similar findings when
cold allodynia is measured. Values
are mean  SEM of 8 to 10 mice.
, P < 0.05 versus Veha-LA acid or
VehBTZ or BL values; x, P < 0.05
versus BTZ-Veha-LA or Vehipsi;
one-way ANOVA and Bonferroni
test. BL, baseline withdrawal
threshold.
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allodynia does not seem confined to bortezomib model as
earlier studies (5, 6, 24) showed a similar role of TRPA1 in
oxaliplatin-evoked sensory neuropathy in mice. In addition,
the TRPV4-resistant component (38) of the mechanical hyper-
algesia evoked by paclitaxel in mice has also been ascribed to
the contribution of TRPA1, whereas TRPA1 appears to be the
sole channel responsible for paclitaxel-evoked cold allodynia
(29). In addition, we found that an oxidative stress scavenger or
a TRPA1 antagonist reversed bortezomib- or oxaliplatin-
evoked hypersensitivity selectively on the treated paw, when
they were given locally by i.pl. administration. This finding
indicates that TRPA1 sensitization/activation occurs at the
very terminal region of nociceptive primary afferents, and that
channel inhibition at this peripheral level is sufficient to revert
the sensory neuropathy.
The protective effect of HC-030031 or a-lipoic acid when
administered (either systemically or locally) at day 7 after
bortezomib administration, although complete, was transient,
lasting no longer than 120 minutes. This is probably due to the
pharmacokinetic properties of the 2 drugs, as indicated by
previous studies in different models of nociception or
hyperalgesia/allodynia (47, 48). In contrast to the transient
reversal produced by pharmacologic treatments when the
hypersensitivity is already established, in TRPA1-deficient
Figure 4. BTZ increases transiently oxidative stress in plasma and early and short-term treatment with HC and a-LA permanently prevents the development
of mechanical, cold, and chemical hypersensitivity evoked by BTZ in mice. A, BTZ (1 mg/kg i.p.) transiently increases carboxy-methyl-lysine (CML)
plasma levels in mice. Both HC (300 mg/kg i.g.) and a-LA (100 mg/kg i.g. 15 minutes before and 3 times at 90-minute intervals each after BTZ treatment)
prevent the development and maintenance of chemical hyperalgesia (B and C) as well as mechanical (D and F) and cold (E and G) allodynia evoked
byBTZ (1mg/kg i.p.). Veh, of BTZ, HC, ora-LA. Values aremeanSEMof 8 to 10mice. ,P < 0.05 versus BL in A, VehHC-VehBTZ in B, D, and E, or Veha-LA-
VehBTZ in C, F, and G; x, P < 0.05 versus VehHC-BTZ in B, D, and E or Veha-LA-BTZ- in C, F, and G; one-way ANOVA and Bonferroni test. BL, basal level of
CML in A and baseline withdrawal threshold in D–G.
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mice hypersensitivity to bortezomib or oxaliplatin (6) does
not develop. These genetic findings and biochemical evi-
dence of the transient increase in plasma CML suggest that
early phenotypic changes of TRPA1, presumably associated
with the oxidative burst, which are responsible for the
development and maintenance of the hypersensitivity, occur
a few hours after chemotherapeutic drug administration. To
identify the critical role of these early events for the man-
ifestation of the enduring hypersensitivity condition by
anticancer drug, we designed an experiment in which HC-
030031 or a-lipoic acid were given shortly before and for
approximately 6 hours after bortezomib or oxaliplatin treat-
ment. These treatments not only blocked the onset of the
hypersensitivity, but, rather surprisingly, completely and
stably prevented its development and maintenance. Of
interest for translating the present observation to the clin-
ical perspective, the permanent protective effect by early and
short-term treatment with the TRPA1 antagonist was also
observed when it was repeated after a second bortezomib
administration. Although it is not possible to replicate in
mice the exact condition experienced by patients, these
additional findings suggest a possible treatment schedule
to prevent the sensory neuropathy in patients when TRPA1
antagonists are clinically available.
Figure 5. Oxaliplatin transiently increases oxidative stress in plasma, and early and short-term treatment with HC and a-LA permanently prevents the
development of mechanical, cold, and chemical hypersensitivity evoked by BTZ in mice. A, oxaliplatin (OXA; 3 mg/kg i.p.) transiently increases CML plasma
levels in mice. Both HC (300 mg/kg i.g.) and a-LA (100 mg/kg i.g. 15 minutes before and 3 times at 90-minute intervals each after BTZ treatment)
prevent the development and maintenance of chemical hyperalgesia (B and C) as well as mechanical (D and F) and cold (E and G) allodynia evoked by
OXA (3 mg/kg i.p.). Veh, vehicle of OXA, HC, or a-LA. Values are mean  SEM of 8 to 10 mice. , P < 0.05 versus BL in A, VehHC-VehOXA in B, D, and E or
Veha-LA-VehOXA in C, F, andG; x,P < 0.05 versus VehHC-OXA in B, D, and E or Veha-LA-OXA in C, F, andG; one-way ANOVA andBonferroni test. BL, basal
level of CML in A and baseline withdrawal threshold in D–G.
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Taken together, these findings indicate that TRPA1, via its
activation by oxidative stress by-products, is necessary and
sufficient to produce a sensory neuropathy paradigm in mice
following a single administration of different chemotherapeu-
tics. Oxaliplatin (6), paclitaxel (29), and bortezomib failed to
evoke any calcium response in cultured TRPA1-expressing
neurons, thus excluding that these drugs may directly target
the channel. However, in vitro findings support the alternative
explanation, as indicated by in vivo results, that chemothera-
peutic agents act indirectly by generating oxidative stress
by-products (3, 8, 9, 23), which in turn sensitize/activate TRPA1
in sensory neurons.
TRPA1 is apparently required for those early (within 6–8
hours) phenotypic changes that eventually result in the long-
term hypersensitivity to specific (AITC) and nonspecific
(pressure or cold) stimuli caused by exposure to different
chemotherapeutic agents in mice. Although some reports
have shown changes in TRP expression in different rodent
models of CIPN, under the present experimental circum-
stances, no change in TRPA1 protein expression in nocicep-
tive neurons was found. The molecular mechanism respon-
sible for the TRPA1-mediated hypersensitivity phenotype,
produced by chemotherapeutic agents remains unknown.
Nevertheless, present experiments with bortezomib and
oxaliplatin identify the early phase (a few hours) that
follows chemotherapeutic drug administration as the key
step when, most likely through oxidative stress by-products,
TRPA1 is activated/sensitized. These early events result in a
prolonged (several days) condition of hypersensitivity that
markedly mimics the long-lasting duration of CIPN in
patients treated with bortezomib or oxaliplatin. If ROS
scavengers, most likely because of poor pharmacokinetics,
could not represent a suitable and effective treatment for
CIPN, the present findings suggest a novel therapeutic
schedule to prevent CIPN in patients, based on TRPA1
antagonists given before and shortly after each administra-
tion of anticancer medicines.
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Figure 6. A repeated early and short-term treatment with HC prevents the development of mechanical and cold hypersensitivity evoked by a second BTZ
treatment in mice. A, schematic representation of HC (300 mg/kg, i.g.) and BTZ (1 mg/kg, i.p.) treatment. A group of mice are treated with HC or its
vehicle 15 minutes before and shortly after (3 times at 90-minute intervals each) a first BTZ or vehicle administration. At day 6 after the first BTZ
administration, all mice receive a second BTZ (1 mg/kg, i.p.) or vehicle administration. Mice pretreated with HC after the first BTZ dose are subdivided into
2 groups. One group is treated a second time with HC (300 mg/kg, i.g.) and a second group with its vehicle 15 minutes before and shortly after (3 times
at 90-minute intervals each) BTZ administration. The second early and short-term treatment with HC totally prevents the development of mechanical
and cold hypersensitivity (B, C). B and C, mice treated with BTZ and HC vehicle develop mechanical and cold hypersensitivity, a response that is further
increased by the second treatment with BTZ andHC vehicle. Values aremeanSEMof 8 to 10mice. ,P < 0.05 versus VehHC-VehBTZ in B andC; x,P < 0.05
versus VehHC-BTZ in B and C; #, P < 0.05 versus VehHC-BTZ or HC/BTZ-VehHC/BTZ; †, P < 0.05 versus HC/BTZ-VehHC/BTZ one-way ANOVA and
Bonferroni test. BL, baseline withdrawal threshold.
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